Bayer's dispute with Mylan over rivaroxaban treatment claims added another cardiovascular-drug case to the 2025 Hatch-Waxman archive.
The asserted method claims involved reducing the risk of myocardial infarction, stroke, or cardiovascular death through administration of rivaroxaban and aspirin in defined patient populations.
For pharmaceutical patent strategy, the case is a useful method-of-treatment entry. Clinical endpoints, dosing language, and patient-population limits can decide both infringement and validity pressure.
The broader business issue is generic launch timing for a high-value drug category, making the appeal relevant beyond the doctrinal details.